Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 1Leukemia 1

Interventions

Azacitidine 41Cytarabine 27fludarabine phosphate 25Cyclophosphamide 23venetoclax 21fludarabine 21Peripheral Blood Stem Cell Transplantation 20Mycophenolic Acid 17Filgrastim 17Decitabine 17Tacrolimus 16Whole-Body Irradiation 15ruxolitinib 14Cyclosporine 14Busulfan 14Melphalan 12Methotrexate 10Imatinib Mesylate 10Stem Cell Transplantation 9Antilymphocyte Serum 8Alemtuzumab 8nilotinib 7decitabine and cedazuridine drug combination 7Granulocyte Colony-Stimulating Factor 7Rituximab 6Injections 6Idarubicin 6Dasatinib 6Clofarabine 6AP 1903 reagent 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × CYC065 × Myeloid × Clear all
NCT05168904 2024-02-08

A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)

Cyclacel Pharmaceuticals, Inc.

Phase 1/2 Suspended
210 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡